Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 592 PK study in healthy Japanese subjects
NCT05885451Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efavaleukin alfa in chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration, Time of Maximum Observed Concentration and 2 more. Started Jan 2019; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05885451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885451.